Anti-Mouse_Rat Foxp3 FITC 25 ug
- Known as:
- Antibody toMouse_Rat Foxp3 fluorecein 25 ug
- Catalog number:
- 11-5773-80
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse_Rat Foxp3 FITC 25
Related genes to: Anti-Mouse_Rat Foxp3 FITC 25 ug
- Gene:
- FOXP3 NIH gene
- Name:
- forkhead box P3
- Previous symbol:
- IPEX
- Synonyms:
- JM2, XPID, AIID, PIDX, DIETER, SCURFIN
- Chromosome:
- Xp11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-05
- Date modifiied:
- 2019-04-23
Related products to: Anti-Mouse_Rat Foxp3 FITC 25 ug
Related articles to: Anti-Mouse_Rat Foxp3 FITC 25 ug
- Given the early recurrence of brain metastasis (BM), identifying factors that drive BM progression is of clinical interest. This study investigates genetic, epigenetic, and inflammatory signatures in progressive BM following different therapeutic approaches. - Source: PubMed
Publication date: 2026/08/13
Steindl ArianeStarzer Angelika MTomasich ErwinKleinberger MarkusBerchtold LuziaEckert FranziskaWidhalm GeorgGatterbauer BrigitteHainfellner Johannes AWozelka-Oltjan LisaErguener BekirSchuster MichaelBock ChristophHeller GerwinPreusser MatthiasBerghoff Anna S - Head and neck squamous cell carcinoma (HNSCC) exhibits a profoundly immunosuppressive tumor microenvironment (TME) enriched for myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and dysfunctional CD8⁺ T cells, limiting therapeutic benefit from immune checkpoint blockade. Macrophage migration inhibitory factor (MIF) is elevated in HNSCC and linked to poor outcomes, yet the cellular source and functional role of tumor-promoting MIF in shaping antitumor immunity remain unclear. - Source: PubMed
Publication date: 2026/08/18
Shrestha SuvekshyaLamenza FelipeKazmierowicz NatalieNyati Kishan KumarJagadeesha SushmithaRamalingam RaviKehres ReeganUpadhaya PujaSiddiqui ArhamMasood ShaheerYade MassarDasari SonaliOghumu Steve - Esophageal squamous cell carcinoma is the most common histological subtype of esophageal cancer, and novel therapeutic strategies, including immunotherapy, are increasingly needed to improve outcomes in advanced-stage disease. Identifying patients who may benefit from immunotherapy through individualized risk stratification and reliable prognostic biomarkers is therefore essential. This study aims to evaluate the association between tumor-infiltrating lymphocyte (TIL) subtypes (CD4, CD8, FOXP3) and their ratios, with clinicopathological features, and tumor budding.The study included 75 patients diagnosed with esophageal squamous cell carcinoma who underwent esophagectomy without receiving preoperative neoadjuvant therapy. Sections best representing the tumor area and TILs were selected, and immunohistochemical staining for CD4, CD8, and FOXP3 was performed. Positive lymphocytes were counted in 10 high-power fields at the invasive front. TIL densities were categorized as low or high based on mean counts. Tumor budding was assessed and classified as low, intermediate, or high grade.According to our results, low CD4 TIL levels were significantly associated with poor histological grade, deeper tumor invasion, advanced pathological stage, and low tumor budding. High FOXP3 TIL expression was associated with invasion depth and lymph node metastasis, whereas superficial tumors showed no high FOXP3 expression. A low FOXP3/CD4 ratio was correlated with longer survival. CD8 TIL density alone showed no significant prognostic impact.In conclusion, combined assessment of TIL subtypes and tumor budding may contribute to improved prognostic stratification and postoperative treatment planning in esophageal squamous cell carcinoma. - Source: PubMed
Publication date: 2026/08/18
Ergul BurcinSener EbruAydin Yener - Cyclophosphamide is widely used in oncology, autoimmune disorders, and transplantation-related conditioning or post-transplant immunosuppression. However, its therapeutic value is limited by hematopoietic and lymphoid toxicity, including leukopenia, neutropenia, anemia, thrombocytopenia, bone marrow suppression, thymic injury, and prolonged impairment of T-cell recovery. These effects may occur after pulsed intravenous administration, high-dose regimens used in transplantation or severe refractory disease, and continuous low-dose/metronomic exposure. Therefore, there is a medical need for pharmacological agents capable of compensating cyclophosphamide-induced hematopoietic and lymphopoietic suppression without causing uncontrolled stimulation of early progenitor cells. - Source: PubMed
Publication date: 2026/08/03
Ten AsselBaktybayeva LayilyaKoshetova ZhanargulKoizhaiganova RaushanDaulet GuldanaZharkynbek TolganayYu Valentina - Islet transplantation is an appropriate treatment for selected individuals with type 1 diabetes mellitus and hypoglycaemia unawareness. The gold standard of maintenance immunosuppression to prevent allograft rejection is calcineurin inhibitor-based therapy; however, side effects warrant exploration of alternative immunosuppression. The co-stimulatory blocker belatacept and the mammalian target of rapamycin inhibitor sirolimus have demonstrated clinical benefit in solid organ transplantation, but efficacy in human islet transplantation is unknown. - Source: PubMed
Publication date: 2026/08/17
Rogers Natasha MHu MinJimenez-Vera ElviraGabor HughSharma Preeti PEtherton ColleenLoudovaris TomHawthorne Wayne JDrogemuller Chris JTorpy David JHolmes-Walker Deborah JGloss BrianGrey Shane TGoodman DavidCoates P TobyKay Tom WO'Connell Philip J